BACKGROUND: Newborn screening (NBS) for Krabbe disease (KD) in New York and Missouri is conducted by measuring galactocerebrosidase (GALC) activity using tandem mass spectrometry (MS/MS). These NBS efforts have shown that the incidence of KD is unexpectedly low (1:400,000) while many individuals (ca. 1:6000) with reduced GALC activity and genotypes of uncertain significance are detected and subjected to follow up testing. Psychosine (PSY) is a putative marker of KD progression and can be measured in dried blood spots (DBS). We sought to determine the role that PSY levels play in NBS for KD, follow up, and treatment monitoring. METHODS: PSY was eluted from DBS with methanol containing N,N-dimethyl-D-erythro-sphingosine as internal standard (IS). Liquid chromatography-MS/MS was conducted over 17 minutes in the multiple reaction monitoring positive mode to follow the precursor to product species transitions for PSY and IS. Separation of the structural isomers PSY and glucosylsphingosine was accomplished by hydrophilic interaction liquid chromatography. RESULTS: Pre-analytical and analytical factors were studied and revealed satisfactory results. PSY was also measured in DBS collected from controls (range: <8 nmol/L, N = 220), KD patients at various disease stages (range: 8-112, N = 26), and GALC mutation carriers (range: <15 nmol/L, N = 18). CONCLUSIONS: PSY measurement in DBS could serve as a 2nd tier assay in NBS for KD, simplify and reduce the cost of follow up protocols, help determine disease progression, and be used to monitor KD patients following hematopoietic stem cell transplantation. However, additional chronological measurements of PSY in KD patients are required to confirm these possibilities.
BACKGROUND: Newborn screening (NBS) for Krabbe disease (KD) in New York and Missouri is conducted by measuring galactocerebrosidase (GALC) activity using tandem mass spectrometry (MS/MS). These NBS efforts have shown that the incidence of KD is unexpectedly low (1:400,000) while many individuals (ca. 1:6000) with reduced GALC activity and genotypes of uncertain significance are detected and subjected to follow up testing. Psychosine (PSY) is a putative marker of KD progression and can be measured in dried blood spots (DBS). We sought to determine the role that PSY levels play in NBS for KD, follow up, and treatment monitoring. METHODS: PSY was eluted from DBS with methanol containing N,N-dimethyl-D-erythro-sphingosine as internal standard (IS). Liquid chromatography-MS/MS was conducted over 17 minutes in the multiple reaction monitoring positive mode to follow the precursor to product species transitions for PSY and IS. Separation of the structural isomers PSY and glucosylsphingosine was accomplished by hydrophilic interaction liquid chromatography. RESULTS: Pre-analytical and analytical factors were studied and revealed satisfactory results. PSY was also measured in DBS collected from controls (range: <8 nmol/L, N = 220), KDpatients at various disease stages (range: 8-112, N = 26), and GALC mutation carriers (range: <15 nmol/L, N = 18). CONCLUSIONS: PSY measurement in DBS could serve as a 2nd tier assay in NBS for KD, simplify and reduce the cost of follow up protocols, help determine disease progression, and be used to monitor KDpatients following hematopoietic stem cell transplantation. However, additional chronological measurements of PSY in KDpatients are required to confirm these possibilities.
Authors: Joseph J Orsini; Mark A Morrissey; Laura N Slavin; Matthew Wojcik; Chad Biski; Monica Martin; Joan Keutzer; X Kate Zhang; Wei-Lien Chuang; Carole Elbin; Michele Caggana Journal: Clin Biochem Date: 2009-02-09 Impact factor: 3.281
Authors: Patricia K Duffner; Michele Caggana; Joseph J Orsini; David A Wenger; Marc C Patterson; Carl J Crosley; Joanne Kurtzberg; Georgianne L Arnold; Maria L Escolar; Darius J Adams; Mary R Andriola; Alan M Aron; Emma Ciafaloni; Alexandra Djukic; Richard W Erbe; Patricia Galvin-Parton; Laura E Helton; Edwin H Kolodny; Barry E Kosofsky; David F Kronn; Jennifer M Kwon; Paul A Levy; Jill Miller-Horn; Thomas P Naidich; Joan E Pellegrino; James M Provenzale; Stanley J Rothman; Melissa P Wasserstein Journal: Pediatr Neurol Date: 2009-04 Impact factor: 3.372
Authors: Hongling Zhu; Aurora Lopez-Rosas; Xi Qiu; Richard B Van Breemen; Ernesto R Bongarzone Journal: Arch Pathol Lab Med Date: 2012-07 Impact factor: 5.534
Authors: Jacqueline A Hawkins-Salsbury; Archana R Parameswar; Xuntian Jiang; Paul H Schlesinger; Ernesto Bongarzone; Daniel S Ory; Alexei V Demchenko; Mark S Sands Journal: J Lipid Res Date: 2013-09-04 Impact factor: 5.922
Authors: Ludovico Cantuti Castelvetri; Maria I Givogri; Amy Hebert; Benjamin Smith; Yuyu Song; Agnieszka Kaminska; Aurora Lopez-Rosas; Gerardo Morfini; Gustavo Pigino; Mark Sands; Scott T Brady; Ernesto R Bongarzone Journal: J Neurosci Date: 2013-06-12 Impact factor: 6.167
Authors: Thomas J Langan; Amy L Barcykowski; Jonathan Dare; Erin C Pannullo; Leah Muscarella; Randy L Carter Journal: J Neurosci Res Date: 2016-11 Impact factor: 4.164
Authors: Hsuan-Chieh Liao; Zdenek Spacil; Farideh Ghomashchi; Maria L Escolar; Joanne Kurtzberg; Joseph J Orsini; Frantisek Turecek; C Ronald Scott; Michael H Gelb Journal: Clin Chem Date: 2017-06-07 Impact factor: 8.327
Authors: Rohini Sidhu; Christina R Mikulka; Hideji Fujiwara; Mark S Sands; Jean E Schaffer; Daniel S Ory; Xuntian Jiang Journal: Biomed Chromatogr Date: 2018-04-26 Impact factor: 1.902
Authors: M L Escolar; B T Kiely; E Shawgo; X Hong; M H Gelb; J J Orsini; D Matern; M D Poe Journal: Mol Genet Metab Date: 2017-05-22 Impact factor: 4.797